The U.S. administration under former President Donald Trump has announced plans to impose escalating tariffs on pharmaceutical imports, starting with a small duty and potentially rising to 250% within 18 months. This aggressive trade stance reflects ongoing Section 232 investigations into pharmaceuticals and semiconductors, following prior tariffs on metals. Industry analysts express concern over the potential disruption to global biopharma supply chains and pricing dynamics amid concurrent Medicare price negotiations and most-favored-nation pricing pressures. The administration's actions signal a significant regulatory shakeup with wide-reaching impacts on pharma trade policies.